LESSONS LEARNED from EARLY-STAGE CLINICAL TRIALS for DIABETIC NEPHROPATHY
Expert Opin Investig Drugs. 2024 Mar 11. doi: 10.1080/13543784.2024.2326025. Online ahead of print.ABSTRACTINTRODUCTION: The evolution of treatment for diabetic nephropathy illustrates how basic biochemistry and physiology have led to new agents such as SGLT2 inhibitors and mineralocorticoid blockers. Conversely, clinical studies performed with these agents have suggested new concepts for investigational drug development. We reviewed currently available treatments for diabetic nephropathy and then analyzed early clinical trials of new agents to assess potential for future treatment modalities.AREAS COVERED: We searched Cli...
Source: Expert Opinion on Investigational Drugs - March 11, 2024 Category: Drugs & Pharmacology Authors: Marc Rendell Source Type: research
Effect of sodium –glucose cotransporter 2 inhibitors on serum low‐density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus
ConclusionsLDL-C levels and statin medication at baseline influence changes in LDL-C after SGLT2 inhibitors treatment in Japanese patients with type 2 diabetes. (Source: Journal of Diabetes Investigation)
Source: Journal of Diabetes Investigation - March 9, 2024 Category: Endocrinology Authors: Tasuku Imada,
Naoto Katakami,
Hirotaka Watanabe,
Shuhei Nishina,
Shugo Sasaki,
Mitsuyoshi Takahara,
Iichiro Shimomura,
Tsunehiko Yamamoto Tags: Original Article Source Type: research
SGLT2i improves kidney senescence by down-regulating the expression of LTBP2 in SAMP8 mice
J Cell Mol Med. 2024 Mar;28(6):e18176. doi: 10.1111/jcmm.18176.ABSTRACTSenescent kidney can lead to the maladaptive repairment and predispose age-related kidney diseases. Here, we explore the renal anti-senescence effect of a known kind of drug, sodium-dependent glucose transporters 2 inhibitor (SGLT2i). After 4 months intragastrically administration with dapagliflozin on senescence-accelerated mouse prone 8 (SAMP8) strain mice, the physiologically effects (lowering urine protein, enhancing glomerular blood perfusion, inhibiting expression of senescence-related biomarkers) and structural changes (improving kidney atrophy, ...
Source: J Cell Mol Med - March 8, 2024 Category: Molecular Biology Authors: Lu Zeng Jie Li Fanfan Gao Yangyang Song Limin Wei Ning Qu Shengnan Chen Xue Zhao Zitong Lei Wenya Cao Lei Chen Hongli Jiang Source Type: research
SGLT2i improves kidney senescence by down-regulating the expression of LTBP2 in SAMP8 mice
J Cell Mol Med. 2024 Mar;28(6):e18176. doi: 10.1111/jcmm.18176.ABSTRACTSenescent kidney can lead to the maladaptive repairment and predispose age-related kidney diseases. Here, we explore the renal anti-senescence effect of a known kind of drug, sodium-dependent glucose transporters 2 inhibitor (SGLT2i). After 4 months intragastrically administration with dapagliflozin on senescence-accelerated mouse prone 8 (SAMP8) strain mice, the physiologically effects (lowering urine protein, enhancing glomerular blood perfusion, inhibiting expression of senescence-related biomarkers) and structural changes (improving kidney atrophy, ...
Source: Molecular Medicine - March 8, 2024 Category: Molecular Biology Authors: Lu Zeng Jie Li Fanfan Gao Yangyang Song Limin Wei Ning Qu Shengnan Chen Xue Zhao Zitong Lei Wenya Cao Lei Chen Hongli Jiang Source Type: research
Early SGLT2 inhibitor use is associated with improved left atrial strain following acute coronary syndrome
CONCLUSION: In patients with ACS and T2D, addition of empagliflozin to standard ACS therapy prior to discharge is associated with improved LA function.PMID:38456717 | DOI:10.1080/00015385.2024.2324221 (Source: Acta Cardiologica)
Source: Acta Cardiologica - March 8, 2024 Category: Cardiology Authors: Amro Sehly Albert He Abdul Rahman Ihdayhid Christine Grey Scott O'Connor Gillian Green Matthew Erickson James M Rankin P Gerry Fegan Bu B Yeap Girish Dwivedi Nick S R Lan Source Type: research
A Randomized Crossover Trial of Mixed Meal Tolerance Test Response in People with Type 1 Diabetes on Insulin Pump Therapy and YG1699 or Dapagliflozin
Clin Pharmacol Ther. 2024 Mar 8. doi: 10.1002/cpt.3225. Online ahead of print.ABSTRACTYG1699 is a novel inhibitor of sodium-glucose cotransporter 1 (SGLT1) and SGLT2. This double-blind, 3-way crossover trial compared YG1699 to dapagliflozin as an adjunct to insulin in people with type 1 diabetes (T1D) on insulin pump therapy. Treatment periods included four mixed meal tolerance tests (MMTTs) and insulin withdrawal tests per person. Nineteen adults with T1D were randomized to YG1699 10 mg, YG1699 25 mg, and dapagliflozin 10 mg once daily for 1 week in different orders. The primary end point was the difference in area under ...
Source: Clinical Pharmacology and Therapeutics - March 8, 2024 Category: Drugs & Pharmacology Authors: Pablo Lapuerta Silvia Urbina Jiaojuan He Alyssa Wittle Chenghai Li Tong Li Helen Wang Marcus Hompesch Source Type: research
GLP-1 receptor agonists in the treatment of diabetic non-alcoholic steatohepatitis patients
Expert Opin Pharmacother. 2024 Mar 8. doi: 10.1080/14656566.2024.2328796. Online ahead of print.ABSTRACTINTRODUCTION: Nonalcoholic fatty liver disease (NAFLD) is the most common hepatic disease affecting almost 30% of the world population. Approximately 25% of people with NAFLD develop nonalcoholic steatohepatitis (NASH), the fulminant version of the disease. Diabetes mellitus is present in 22.5% of people with NAFLD and 44.60% of individuals with NASH. This review was undertaken to examine the current contribution of glucagon-like peptide 1 (GLP-1) receptor agonists to the pharmacotherapy of diabetic nonalcoholic steatohe...
Source: Expert Opinion on Pharmacotherapy - March 8, 2024 Category: Drugs & Pharmacology Authors: Ernest A Adeghate Source Type: research
SGLT2i improves kidney senescence by down-regulating the expression of LTBP2 in SAMP8 mice
J Cell Mol Med. 2024 Mar;28(6):e18176. doi: 10.1111/jcmm.18176.ABSTRACTSenescent kidney can lead to the maladaptive repairment and predispose age-related kidney diseases. Here, we explore the renal anti-senescence effect of a known kind of drug, sodium-dependent glucose transporters 2 inhibitor (SGLT2i). After 4 months intragastrically administration with dapagliflozin on senescence-accelerated mouse prone 8 (SAMP8) strain mice, the physiologically effects (lowering urine protein, enhancing glomerular blood perfusion, inhibiting expression of senescence-related biomarkers) and structural changes (improving kidney atrophy, ...
Source: J Cell Mol Med - March 8, 2024 Category: Molecular Biology Authors: Lu Zeng Jie Li Fanfan Gao Yangyang Song Limin Wei Ning Qu Shengnan Chen Xue Zhao Zitong Lei Wenya Cao Lei Chen Hongli Jiang Source Type: research
SGLT2i improves kidney senescence by down-regulating the expression of LTBP2 in SAMP8 mice
J Cell Mol Med. 2024 Mar;28(6):e18176. doi: 10.1111/jcmm.18176.ABSTRACTSenescent kidney can lead to the maladaptive repairment and predispose age-related kidney diseases. Here, we explore the renal anti-senescence effect of a known kind of drug, sodium-dependent glucose transporters 2 inhibitor (SGLT2i). After 4 months intragastrically administration with dapagliflozin on senescence-accelerated mouse prone 8 (SAMP8) strain mice, the physiologically effects (lowering urine protein, enhancing glomerular blood perfusion, inhibiting expression of senescence-related biomarkers) and structural changes (improving kidney atrophy, ...
Source: Molecular Medicine - March 8, 2024 Category: Molecular Biology Authors: Lu Zeng Jie Li Fanfan Gao Yangyang Song Limin Wei Ning Qu Shengnan Chen Xue Zhao Zitong Lei Wenya Cao Lei Chen Hongli Jiang Source Type: research
Early SGLT2 inhibitor use is associated with improved left atrial strain following acute coronary syndrome
CONCLUSION: In patients with ACS and T2D, addition of empagliflozin to standard ACS therapy prior to discharge is associated with improved LA function.PMID:38456717 | DOI:10.1080/00015385.2024.2324221 (Source: Acta Cardiologica)
Source: Acta Cardiologica - March 8, 2024 Category: Cardiology Authors: Amro Sehly Albert He Abdul Rahman Ihdayhid Christine Grey Scott O'Connor Gillian Green Matthew Erickson James M Rankin P Gerry Fegan Bu B Yeap Girish Dwivedi Nick S R Lan Source Type: research
A Randomized Crossover Trial of Mixed Meal Tolerance Test Response in People with Type 1 Diabetes on Insulin Pump Therapy and YG1699 or Dapagliflozin
Clin Pharmacol Ther. 2024 Mar 8. doi: 10.1002/cpt.3225. Online ahead of print.ABSTRACTYG1699 is a novel inhibitor of sodium-glucose cotransporter 1 (SGLT1) and SGLT2. This double-blind, 3-way crossover trial compared YG1699 to dapagliflozin as an adjunct to insulin in people with type 1 diabetes (T1D) on insulin pump therapy. Treatment periods included four mixed meal tolerance tests (MMTTs) and insulin withdrawal tests per person. Nineteen adults with T1D were randomized to YG1699 10 mg, YG1699 25 mg, and dapagliflozin 10 mg once daily for 1 week in different orders. The primary end point was the difference in area under ...
Source: Clinical Pharmacology and Therapeutics - March 8, 2024 Category: Drugs & Pharmacology Authors: Pablo Lapuerta Silvia Urbina Jiaojuan He Alyssa Wittle Chenghai Li Tong Li Helen Wang Marcus Hompesch Source Type: research
GLP-1 receptor agonists in the treatment of diabetic non-alcoholic steatohepatitis patients
Expert Opin Pharmacother. 2024 Mar 8. doi: 10.1080/14656566.2024.2328796. Online ahead of print.ABSTRACTINTRODUCTION: Nonalcoholic fatty liver disease (NAFLD) is the most common hepatic disease affecting almost 30% of the world population. Approximately 25% of people with NAFLD develop nonalcoholic steatohepatitis (NASH), the fulminant version of the disease. Diabetes mellitus is present in 22.5% of people with NAFLD and 44.60% of individuals with NASH. This review was undertaken to examine the current contribution of glucagon-like peptide 1 (GLP-1) receptor agonists to the pharmacotherapy of diabetic nonalcoholic steatohe...
Source: Expert Opinion on Pharmacotherapy - March 8, 2024 Category: Drugs & Pharmacology Authors: Ernest A Adeghate Source Type: research
SGLT2i improves kidney senescence by down-regulating the expression of LTBP2 in SAMP8 mice
J Cell Mol Med. 2024 Mar;28(6):e18176. doi: 10.1111/jcmm.18176.ABSTRACTSenescent kidney can lead to the maladaptive repairment and predispose age-related kidney diseases. Here, we explore the renal anti-senescence effect of a known kind of drug, sodium-dependent glucose transporters 2 inhibitor (SGLT2i). After 4 months intragastrically administration with dapagliflozin on senescence-accelerated mouse prone 8 (SAMP8) strain mice, the physiologically effects (lowering urine protein, enhancing glomerular blood perfusion, inhibiting expression of senescence-related biomarkers) and structural changes (improving kidney atrophy, ...
Source: J Cell Mol Med - March 8, 2024 Category: Molecular Biology Authors: Lu Zeng Jie Li Fanfan Gao Yangyang Song Limin Wei Ning Qu Shengnan Chen Xue Zhao Zitong Lei Wenya Cao Lei Chen Hongli Jiang Source Type: research
Early SGLT2 inhibitor use is associated with improved left atrial strain following acute coronary syndrome
CONCLUSION: In patients with ACS and T2D, addition of empagliflozin to standard ACS therapy prior to discharge is associated with improved LA function.PMID:38456717 | DOI:10.1080/00015385.2024.2324221 (Source: Acta Cardiologica)
Source: Acta Cardiologica - March 8, 2024 Category: Cardiology Authors: Amro Sehly Albert He Abdul Rahman Ihdayhid Christine Grey Scott O'Connor Gillian Green Matthew Erickson James M Rankin P Gerry Fegan Bu B Yeap Girish Dwivedi Nick S R Lan Source Type: research
